Remission of Bulimia Nervosa Observed During Administration of Liraglutide and Metformin: A Case Report

Abstract

Objective: Bulimia nervosa, an eating disorder characterized by recurrent binging and purging episodes, is frequently associated with depression. Conventional therapy with antidepressants and cognitive behavioral therapy has poor long-term success. Appetite-regulating gut hormones such as glucagon-like peptide 1 (GLP-1) may be implicated in the pathophysiology, and thus, GLP-1 receptor agonists may be an effective therapy.Methods: A 26-year-old patient with polycystic ovary syndrome (PCOS) on chronic metformin therapy, with reactive hypoglycemia, bulimia nervosa, and depression, unresponsive to antidepressants and psychotherapy, was given a trial of liraglutide 1.2 mg daily to control hunger and prolong satiety.